InCarda Therapeutics is a biopharmaceutical company based in Newark, CA, specializing in a transformative approach to cardiovascular disease. With a focus on atrial fibrillation, their pipeline includes orally inhaled flecainide, offering a novel treatment option for patients.
Driven by a dedicated team of experts and supported by a strong board of directors and investors, InCarda Therapeutics is committed to advancing innovative solutions that address the unmet needs of patients with cardiovascular conditions.
Generated from the website